{"id":"W2418506270","doi":"10.1056/nejmoa1512711","title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":838,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"","keywords":"Ixekizumab; Medicine; Psoriasis; Etanercept; Placebo; Plaque psoriasis; Clinical trial; Interleukin 17; Dermatology; Internal medicine; Tumor necrosis factor alpha; Alternative medicine; Secukinumab; Inflammation; Psoriatic arthritis; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002291133,0.0001740739,0.001111139,0.0004036436,0.00002917953,0.000002274795,0.0001858798,0.0001562457,0.001183338],"category_scores_gemma":[0.001437208,0.00008566388,0.000132571,0.0001670186,0.00007234942,0.00008632321,0.00001799057,0.0001372163,0.00003158253],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004889465,"about_ca_system_score_gemma":0.0001697662,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009079771,"about_ca_topic_score_gemma":0.0000581081,"domain_scores_codex":[0.9977871,0.0005985123,0.001158882,0.0001390259,0.00009180875,0.0002247206],"domain_scores_gemma":[0.9978675,0.001163032,0.0005850453,0.0001624395,0.0001330007,0.00008894243],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.01496086,0.000279166,0.000733586,0.000009463402,0.0003763463,0.00008240342,0.001069291,0.000008450555,0.2042549,0.0001229277,0.009539811,0.7685629],"study_design_scores_gemma":[0.6594738,0.009185801,0.002749345,0.001539438,0.0007290127,0.001267132,0.0003115511,0.000001199107,0.2172817,0.002183668,0.1049844,0.0002928677],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9864787,0.004582148,0.000890937,0.00564512,0.001758746,0.0001758119,0.00004430492,0.000007273546,0.000416975],"genre_scores_gemma":[0.9963778,0.001016872,0.0001601333,0.0001097752,0.0009583548,0.000002752702,0.000008538206,0.0000116471,0.001354145],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.76827,"threshold_uncertainty_score":0.9997297,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04471593433998027,"score_gpt":0.3116114006828535,"score_spread":0.2668954663428732,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}